Venous Stents Market: Size, Trends, Growth Analysis & Competitive Outlook (2034)

The Venous Stents Market refers to the global market for implantable devices designed to treat venous disorders-such as deep vein thrombosis, chronic venous insufficiency, and May-Thurner syndrome-by maintaining vessel patency. Driven by rising prevalence of venous disease, expanding endovascular procedures, and continuous product innovation, the market is poised for steady growth. In 2024, the market reached USD 1.10 billion and is projected to grow at a compound annual growth rate (CAGR) of 8.45% from 2025 to 2034, reaching USD 2.48 billion by 2034.

Get a free sample report: https://shorturl.at/H1g7H

Market Overview

Venous stenting involves placing a scaffold (typically a metallic mesh) inside a narrowed or blocked vein to restore normal blood flow. These devices are most frequently used in cases of iliac vein compression (May-Thurner syndrome), post-thrombotic syndrome, and obstruction due to malignancy or fibrosis.

Key advantages include:

Minimally invasive delivery (via catheter-based systems)

Rapid symptomatic relief

Long-term patency

Lower complication rates compared to open surgery

With global aging, rising risk factors (obesity, immobility), and improved diagnostic techniques (duplex ultrasound, CT venography), venous diseases are more frequently identified and treated at earlier stages, expanding the pool of stent candidates.

Market Size & Share

Global Market Valuation (2024): USD 1.10 billion

Forecast (2034): USD 2.48 billion at 8.45% CAGR

Regional Breakdown

North America dominated in 2024 (~45% market share), backed by strong healthcare infrastructure, reimbursement support, and lead in adoption of endovascular solutions.

Europe (particularly Germany, France, UK) holds 25-30% due to specialist vascular centers and integrated venous care approaches.

Asia Pacific is emerging fastest (approx. 9-10% CAGR), propelled by aging demographics, growing procedural volume in China, India, and Japan, and increasing access to minimally invasive care.

Anatomical Distribution

Iliac vein stents represent ~60% of volume (due to high prevalence of May-Thurner syndrome).

Femoral/popliteal segments comprise the remainder.

Product Segmentation

Bare-metal stents currently dominate (cost-effective, established safety profile).

Covered stents are gaining traction for malignant obstructions or re-stenosis risk.

Read full report with table of content: https://shorturl.at/hyOIX

Market Dynamics & Trends

Drivers

Increasing Venous Disease Burden
Rising rates of obesity, sedentary lifestyle, and postoperative status contribute to a surge in DVT and post-thrombotic syndrome cases.

Technological Innovation
Development of nitinol-based self-expanding stents, venous-specific designs (longer lengths, larger diameters), and drug-eluting technologies improve outcomes.

Awareness & Diagnostics
Wider use of duplex ultrasound and CT venography enables early detection and treatment planning.

Reimbursement Policies
Payer recognition of cost savings via improved patency lowers total care expense, supporting venous stent adoption.

Trends

Emergence of dedicated venous stent systems (longer, larger vessels).

Robust clinical trials (e.g., VERNACULAR, FLEXIVO) confirming safety and efficacy.

Minimally invasive venous interventions, offered in outpatient or hybrid OR settings.

Digital health integration for patient follow-up and surveillance.

Market Growth Analysis

At 8.45% CAGR, market expansion is powered by:

Aging Population: Individuals aged 65+ at elevated risk requiring intervention.

Healthcare Expansion: Growing interventional radiology and vascular surgery infrastructures, especially in APAC.

Product Differentiation: Players offering stents engineered specifically for veins (e.g., longer lengths, flexibility) gain preference over improvised arterial stents.

Insurance Coverage Expansion: Vascular care reimbursement helps reduce patient financial burden.

Higher Repeat Intervention Rates: Venous disease recurrences that require stenting sustain segment growth.

Opportunities & Challenges

Opportunities

Emerging Markets: Rapid expansion of private and public vascular facilities across India, China, Latin America.

Product Development: Drug-eluting and biodegradable venous stents remain largely unexplored.

Disease Awareness: Campaigns educating physicians and patients can boost referrals and expand indications.

Combined Devices: Integration of sensors in stents for real-time thrombus detection or blood flow monitoring.

Challenges

Regulatory Hurdles: Longer timelines for approvals in covered drug-eluting products.

Reimbursement Variability: Inconsistent coverage across regional insurance programs.

Cost Constraints: Superior stent technologies remain expensive, particularly in low-income countries.

Complication Concerns: Risk of stent migration, fracture, and restenosis necessitate long-term data and follow-up infrastructure.

Diagnosis Rates: Underdiagnosis of venous disorders in many regions limits patient referrals.

Recent Developments

Abbott Laboratories launched the VenovoTM Venous Stent System with positive trial outcomes and FDA approval.

Boston Scientific introduced the OptiCross Vascular Stent System, demonstrating robust venoplasty results.

Medtronic announced CE marking for its Vici Venous Stent Platform in the EU, targeting iliac disease.

Philips expanded its vascular suite with venous stent offerings alongside IVUS imaging integration.

Shanghai MicroPort rolled out an affordable venous stent for emerging markets, aiming at cost-effective treatment in China.

Jotec GmbH completed a large RCT demonstrating venous stent patency over 12 months.

These events highlight product innovation, clearance gains, and expanding clinical acceptance.

Competitive Analysis: Vendor Landscape
Abbott Laboratories

VenovoTM stent: nickel-titanium self-expanding with high resistance to compression.

Strengths: strong interventional vascular presence and global distribution.

Becton, Dickinson and Company

Leveraging its vascular access products to expand into venous stents.

Strengths: supply chain and hospital relationships.

Bentley (formerly SINTEF/B Spyros Bentley)

Focused on small-diameter venous or peripheral stents.

Niche innovation in Europe.

Boston Scientific

OptiCross and recently acquired venous portfolio.

Strengths: interventional suite integration.

Cardinal Health

Distributor of multiple venous stent brands; pivoting to become market supplier.

Cook Group

Known for peripheral stents; working on larger venous calibers.

Koninklijke Philips

Combines stents with imaging (IVUS) to guide placement.

Medtronic

Vici Venous Stent Platform; global reach backed by established vascular franchise.

W.L. Gore & Associates

Gore VENUS family designed for iliac and vena cava stenting-emphasizes biocompatibility.

Shanghai MicroPort

Cost-competitive stents catered to APAC; aggressively expanding.

Jotec GmbH / Optimed / Medica / Cordis / MicroPort Scientific

Regional leaders with growing clinical trial evidence and EU regulatory presence.

These players compete on innovation, regulatory burdens, pricing, and surgeon preference. Growing trials/follow-up data offer competitive differentiation.

Frequently Asked Questions (FAQ)

What are venous stents used for?
Primarily for treating venous obstructions causing pain, swelling, ulcers, or post-thrombotic syndrome-especially in iliac and femoral veins.

How big is the venous stents market?
The market was USD 1.10 billion in 2024 and is projected to reach USD 2.48 billion by 2034, growing at 8.45% CAGR.

Which region leads the market?
North America leads (~45%), followed by Europe (~30%). APAC is the fastest-growing region.

Which companies dominate this market?
Top companies: Abbott, Medtronic, Boston Scientific, Philips, W.L. Gore, and Shanghai MicroPort, among others.

What are growth drivers?
Drivers include rising venous disease prevalence, aging population, technological innovation, diagnostic access, and improved insurance coverage.

Challenges?
Challenges range from regulatory delays and cost issues to reimbursement disparities and procedural complexity.

What are future trends?
Future trends include venous-specific stents, bioresorbables, embedded sensors, and growing outpatient procedures.

The venous stents market reflects the convergence of advancing cardiovascular intervention, rising incidence of venous disorders, and durable adoption of minimally invasive techniques. From its 2024 valuation of USD 1.10 billion to a forecasted USD 2.48 billion by 2034, this sector offers compelling clinical and commercial opportunity.

Key success factors:

Continued product innovation-venous-specific features, embedded sensors, Luminance research

Regulatory approvals for drug-coated/stent devices

Healthcare access improvements and standardized follow-up

Expanded education and referral systems

For investors and industry players, strategic focus on emerging markets (APAC, Latin America), affordable devices, and early supportive healthcare policy adoption can drive the next wave of growth.

As the global population ages and venous disease becomes more widely diagnosed and treated, venous stents are positioned to remain a cornerstone of endovascular vascular therapy.

Find More Report:

Seizures Drug Pipeline Analysis: https://rb.gy/jm0vdv

Wilson Disease Drug Pipeline Analysis: https://rb.gy/6uoaoy

Sinusitis Drug Pipeline Analysis: https://rb.gy/wzi7my

Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis: https://rb.gy/24kjl0

Psoriatic Arthritis Drug Pipeline Analysis: https://rb.gy/01d7e8

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.